Kezar Life Sciences, Inc. KZR
Set alert
7.29 USD 0.00 0.00%
At close · May 11
7.37 +0.08 +1.10%
After hours · May 11, 4:00 PM ET
7.29 Day range 7.29
5.20 52-week range 11.40
- YTD
- +15.90%
- 1 year
- +72.75%
- Open
- 7.29
- Prev close
- 7.29
- Mkt cap
- 46.99M
- Vol
- 0
- Avg vol
- 108.25K
- EPS
- -13.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.29
- High
- 7.29
- Forward P/E
- -0.62
- Beta
- 0.22
- Short ratio
- 0.93
- Inst. own
- 63.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 7.44
- 200-d avg
- 7.19
- 1y target
- 13.50
2Y chart
Events in this range
- Aug 13, 2024Earnings: -2.8; estimate -3.2; surprise 12.5%
- Aug 13, 2024Earnings: —; estimate -3.2; surprise —%
- Oct 2, 2024Downgrade: HC Wainwright & Co. · Buy → Neutral
- Oct 14, 2024Rating: HC Wainwright & Co. · — → Neutral
- Oct 18, 2024Rating: HC Wainwright & Co. · — → Neutral
- Oct 30, 2024Split: 1 for 10
- Nov 12, 2024Earnings: -2.78; estimate -3.03; surprise 8.25%
- Nov 14, 2024Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Dec 2, 2024Rating: HC Wainwright & Co. · Neutral → Neutral
- Dec 19, 2024Rating: Wells Fargo · Equal-Weight → Equal-Weight
Signals (72)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 20, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| RSI: Overbought | Mar 2, 2026 | 8 months ago |
| RSI: Overbought | Feb 19, 2026 | 8 months ago |
| SMA: Bullish | Feb 11, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| SMA: Bearish | Jan 9, 2026 | 9 months ago |
| RSI: Overbought | Nov 21, 2025 | 11 months ago |
| RSI: Overbought | Nov 14, 2025 | 11 months ago |
| RSI: Overbought | Nov 10, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 17, 2025 | 1 year ago |
| RSI: Overbought | Oct 17, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 17, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 24, 2025 | 1 year ago |
| SMA: Bearish | Jul 23, 2025 | 1 year ago |
| SMA: Bullish | Jul 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 27, 2025 | 1 year ago |
| SMA: Bearish | Jun 25, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 18, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 5, 2025 | 1 year ago |
| SMA: Bearish | Jun 4, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | May 28, 2025 | 1 year ago |
| MACD: Sell Signal | May 27, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| SMA: Bullish | Mar 24, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 6, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 28, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 19, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 12, 2025 | 1 year ago |
| RSI: Oversold | Dec 3, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 18, 2024 | 2 years ago |
| SMA: Bearish | Oct 1, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 1, 2024 | 2 years ago |
| RSI: Oversold | Oct 1, 2024 | 2 years ago |
| SMA: Bullish | Sep 30, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 30, 2024 | 2 years ago |
| RSI: Overbought | Sep 30, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 24, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 18, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 3, 2024 | 2 years ago |
| SMA: Bearish | Aug 28, 2024 | 2 years ago |
| SMA: Bullish | Aug 23, 2024 | 2 years ago |
| SMA: Bearish | Aug 22, 2024 | 2 years ago |
| SMA: Bullish | Aug 21, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 15, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 30, 2024 | 2 years ago |
| SMA: Bullish | Jul 26, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 11, 2024 | 2 years ago |
| RSI: Oversold | Jun 28, 2024 | 2 years ago |
Key statistics
- Market cap
- 46.99M
- Enterprise value
- -91.92M
- Trailing P/E
- 0.00
- Forward P/E
- -0.62
- PEG ratio
- 0.00
- Price / sales
- 6.71
- Price / book
- 0.25
- EPS (TTM)
- -13.12
- Beta
- 0.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.00M
- Revenue growth
- 0.00%
- Free cash flow
- -41.50M
- Total cash
- 164.18M
- Total debt
- 17.61M
- Return on equity
- -51.48%
- Shares outstanding
- 7.30M
- Short % of float
- 2.50%
- 50-day average
- 7.44
- 200-day average
- 7.19
Analyst view
Consensus: buy
Buy
Price target (mean) 13.50 +85.2% upside
Now 7.29
- Target (low)
- 9.00
- Target (mean)
- 13.50
- Target (high)
- 18.00
Ratings (0m) 6 2 buy · 4 hold · 0 sell
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -2.76.
Financials — quick view
KZR Revenue — quarterly 0
KZR Net income — quarterly -5.76M
KZR EPS — quarterly -0.78
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -3.03 | -2.78 | +0.25 | +8.25% |
| Aug 13, 2024 | Jun 1, 2024 | -3.20 | -2.80 | +0.40 | +12.50% |
| Aug 13, 2024 | Jun 1, 2024 | -3.20 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -3.40 | -3.00 | +0.40 | +11.76% |
| May 9, 2024 | Mar 1, 2024 | -3.40 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -3.90 | -3.50 | +0.40 | +10.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Dec 2, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 14, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 18, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Oct 14, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Oct 2, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
About Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kezarlifesciences.com
News
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS
- Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
- Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
- Lifecore Biomedical (NASDAQ:LFCR) and Kezar Life Sciences (NASDAQ:KZR) Head-To-Head Review
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
- KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
- Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages
Your note
Sign in to keep a note on KZR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FOWLER JOHN FRANKLIN | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 9, 2022 | 436,115 |
| KIRK CHRISTOPHER J | Director | Conversion of Exercise of derivative security | Jul 19, 2023 | 431,348 |
| MORNINGSIDE VENTURE INVESTMENTS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 5, 2023 | 5,447,990 |
| SCHILLER MARK C | Officer | Sale | Jul 1, 2024 | 33,007 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 18.34% | 1,338,273 | 8.62M | Sep 29, 2024 |
| Suvretta Capital Management, LLC | 9.82% | 716,759 | 4.62M | Sep 29, 2024 |
| Avidity Partners Management, LP | 6.89% | 502,600 | 3.24M | Sep 29, 2024 |
| Tang Capital Management, LLC | 4.99% | 364,030 | 2.34M | Sep 29, 2024 |
| Vanguard Group Inc | 3.76% | 274,111 | 1.77M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 3.44% | 251,178 | 1.62M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.57% | 187,756 | 1.21M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.05% | 76,473 | 492.49K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.49% | 35,834 | 230.77K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 10,810 | 69.62K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 8,522 | 54.88K | Oct 30, 2024 |
| Price (T.Rowe) U.S. Equities Trust | 0.11% | 8,360 | 53.84K | Sep 29, 2024 |